Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 6/20 | 0.68 |
| ▸ | POR | P16435 | 6/20 | 0.68 |
| ▸ | MAPT | P10636 | 8/20 | 0.61 |
| ▸ | MEN1 | O00255 | 6/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.61 |
| ▸ | HPGD | P15428 | 5/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.61 |
| ▸ | HKDC1 | Q2TB90 | 4/20 | 0.59 |
| ▸ | HTT | P42858 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | CDC25A | P30304 | 1/20 | 0.59 |
| ▸ | CDC25B | P30305 | 1/20 | 0.59 |
| ▸ | CDC25C | P30307 | 1/20 | 0.59 |
| ▸ | MPI | P34949 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.58 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5940497 | 0.81 | NQO1 (1.00) | NQO1PORMAPTMEN1KMT2A | |
| SCHEMBL5940235 | 0.81 | NQO1 (1.00) | NQO1PORMAPTMEN1KMT2A | |
| SCHEMBL28845339 | 0.79 | NQO1 (1.00) | NQO1PORMAPTMEN1KMT2A | |
| SCHEMBL24119165 | 0.79 | MAPT (0.53) | NQO1PORMAPTMEN1KMT2A | |
| SCHEMBL24119166 | 0.78 | NQO1 (0.72) | NQO1PORMAPTMEN1KMT2A | |
| SCHEMBL16152313 | 0.77 | EED (0.69) | NQO1PORMAPTMEN1KMT2A | |
| SCHEMBL24119085 | 0.76 | MAPT (0.58) | NQO1PORMAPTMEN1KMT2A | |
| SCHEMBL24119167 | 0.76 | NQO1 (0.68) | NQO1PORMAPTMEN1KMT2A | |
| SCHEMBL801214 | 0.75 | MAPT (1.00) | MAPTMEN1KMT2AKDM4EHPGD | |
| Tanshinone I SCHEMBL244391 | 0.74 | TDP1 (1.00) | NQO1PORMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200179417-A1 | COMBINATION CHEMOTHERAPIES | SYSTEMS ONCOLOGY, LLC (US) | 2020-06-11 | — | — | US | claimed |
| CN-115141204-B | Naphthalene [1,2-b ] furan-4, 5-dione derivative, preparation and application thereof | 浙江大学 | 2024-01-02 | — | — | CN | disclosed |
| US-20230255904-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | NADIANBIO LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230255904-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | NADIANBIO LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
| CN-115141204-A | Naphthalene [1,2-b ] furan-4,5-diketone derivative and preparation and application thereof | 浙江大学 | 2022-10-04 | — | — | CN | disclosed |
| US-20210395283-A1 | COMPOUND, COMPLEX, PREPARATION METHOD THEREOF, AND USE THEREOF | JIANGSU OXIRANCHEM CO., LTD. (CN) | 2021-12-23 | — | — | US | disclosed |
| US-20200179417-A1 | COMBINATION CHEMOTHERAPIES | SYSTEMS ONCOLOGY, LLC (US) | 2020-06-11 | — | — | US | disclosed |
| US-9066922-B2 | Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases | MD BIOALPHA CO., LTD. (KR) | 2015-06-30 | — | — | US | disclosed |
| US-9066922-B2 | Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases | MD BIOALPHA CO., LTD. (KR) | 2015-06-30 | — | — | US | disclosed |
| US-20140154319-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CARDIAC DISEASE | KWAK TAEHWAN (KR) | 2014-06-05 | — | — | US | disclosed |
| WO-2009082124-A2 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF GLAUCOMA | MAZENCE INC. (KR) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009048251-A2 | PHARMACEUTICAL COMPOSITION CONTAINING MICRONIZED PARTICLES OF NAPHTHOQUINONE-BASED COMPOUND | MAZENCE INC. (KR) | 2009-04-16 | — | — | WO | disclosed |
| US-20080146655-A1 | Pharmaceutical Composition for the Treatment or Prevention of Diseases Involving Obesity, Diabetes, Metabolic Syndrome, Neuro-Degenerative Diseases and Mitochondria Dyfunction Diseases | MD BIOALPHA CO., LTD. (KR) | 2008-06-19 | — | — | US | disclosed |
| US-20080146655-A1 | Pharmaceutical Composition for the Treatment or Prevention of Diseases Involving Obesity, Diabetes, Metabolic Syndrome, Neuro-Degenerative Diseases and Mitochondria Dyfunction Diseases | MD BIOALPHA CO., LTD. (KR) | 2008-06-19 | — | — | US | disclosed |
| WO-2008066295-A1 | PHARMACEUTICAL COMPOSITION CONTAINING NAPHTHOQUINONE-BASED COMPOUND FOR INTESTINE DELIVERY SYSTEM | MAZENCE INC. (KR) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008066294-A1 | PHARMACEUTICAL COMPOSITION CONTAINING MICRONIZED PARTICLE OF NAPHTHOQUINONE-BASED COMPOUND | MAZENCE INC. (KR) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008066301-A1 | ANTICANCER COMPOSITION CONTAINING NAPHTHOQUINONE-BASED COMPOUND FOR INTESTINE DELIVERY SYSTEM | MAZENCE INC. (KR) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008066297-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF RESTENOSIS | MAZENCE INC. (KR) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008066298-A1 | COMPOUND FOR TREATMENT OR PREVENTION OF PROSTATE-RELATED DISEASES AND PHARMACEUTICAL COMPOSITION OF COLON DELIVERY SYSTEM CONTAINING THE SAME | MAZENCE INC. (KR) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008066299-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF DISEASES INVOLVING IMPOTENCE | MAZENCE INC. (KR) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230255904-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | PDCD1, CD274, PDCD10 | NQO1 17/4885POR 3903/4885MAPT 684/4885 |
| US-20080146655-A1 | Pharmaceutical Composition for the Treatment or Prevention of Diseases Involving Obesity, Diabetes, Metabolic Syndrome, Neuro-Degenerative Diseases and Mitochondria Dyfunction Diseases | NDUFAB1, CS, NLN | NQO1 260/4885POR 902/4885MAPT 308/4885 |
| US-20140154319-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CARDIAC DISEASE | TNNT2, TNNC1, TNNI3 | NQO1 773/4885POR 1472/4885MAPT 2106/4885 |
| US-20210395283-A1 | COMPOUND, COMPLEX, PREPARATION METHOD THEREOF, AND USE THEREOF | NOP10, C9, RPP30 | NQO1 214/4885POR 273/4885MAPT 4841/4885 |
| US-20200179417-A1 | COMBINATION CHEMOTHERAPIES | ROS1, HRAS, TP53 | NQO1 21/4885POR 3352/4885MAPT 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.